Press Releases

InVivo Therapeutics Announces Publication in Neurosurgery of Lifetime Hospitalization Costs for Thoracic Spinal Cord Injury Patients by Severity Grade

Published: September 5, 2017

– Costs substantially lower for patients with less severe AIS Grade – CAMBRIDGE, Mass. (September 5, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the publication of an article titled “Relationship of American Spinal Injury Association Impairment Scale Grade to Post-injury Hospitalization and Costs in Thoracic Spinal Cord Injury” in the journal Neurosurgery. Neurosurgery is the official journal of the Congress of Neurological Surgeons. The article estimates the lifetime economic costs associated with hospitalizations in relation to American Spinal Injury Association Impairment Scale (AIS) grade. AIS grades are widely-used measures of spinal cord injury (SCI) severity that range from […]

View Article
InVivo Therapeutics Announces Strategic Corporate Restructuring

Published: August 28, 2017

–  Company Focuses Resources on INSPIRE  – CAMBRIDGE, Mass. (August 28, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that it is executing a strategic restructuring in order to focus on The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury The strategic restructuring will allow the company to concentrate its efforts on reopening patient enrollment for INSPIRE, completing INSPIRE, and filing a Humanitarian Device Exemption (HDE) submission for the Neuro-Spinal Scaffold. The INSPIRE Study is designed to demonstrate the safety and […]

View Article
InVivo Therapeutics Announces Exchange of Certain Warrants for Common Stock

Published: August 10, 2017

– Eliminates Vast Majority of Adverse Warrants – CAMBRIDGE, Mass. (August 10, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that it had exchanged certain outstanding warrants that were issued as part of a financing in 2014 (the “2014 Warrants”) for shares of the company’s common stock. The 2014 Warrants have anti-dilution features such that the exercise price of the warrants decreases if the company sells shares of its common stock for consideration below the exercise price of the 2014 Warrants, and upon certain other events. In addition, the number of warrants increases inversely to the exercise price decrease. […]

View Article
InVivo Therapeutics Provides Business Update and Reports 2017 Second Quarter Financial Results

Published: August 8, 2017

CAMBRIDGE, Mass. (August 8, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today provided a general business update and reported financial results for the quarter ended June 30, 2017. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “In the second quarter, we continued to make significant progress at InVivo. During the quarter, we enrolled four more patients into INSPIRE, and we now have 16 patients in follow-up. One of these patients improved from complete AIS A SCI to motor incomplete AIS C SCI at the one-month visit. We also announced that two patients who had previously converted to AIS B had […]

View Article
InVivo Therapeutics to Present at Canaccord Genuity’s 37th Annual Growth Conference

Published: August 8, 2017

CAMBRIDGE, Mass. (August 8, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the 37th Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2017 at 2:30 PM Eastern Time at the InterContinental Boston in Boston, MA. This is the first time that the company has been invited to present at this conference. Mr. Perrin’s presentation will feature recent updates to the company’s Neuro-Spinal Scaffold™ program. A live webcast will be available at http://wsw.com/webcast/canaccord26/nviv and a webcast replay will be available at the same address approximately one hour after the […]

View Article
InVivo Therapeutics Announces Updates on the INSPIRE Study

Published: July 31, 2017

– Announces Two New Patient Conversions – – Implements Temporary Enrollment Halt – CAMBRIDGE, Mass. (July 31, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today provided an update on the progress of the company’s INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), which is designed to demonstrate the safety and probable benefit of the Neuro-Spinal Scaffold™ for the treatment of complete thoracic spinal cord injury (SCI).  The primary endpoint of the study is defined as improvement in ASIA Impairment Scale (AIS) grade from […]

View Article
InVivo Therapeutics Announces Stanford Medicine as New Site for INSPIRE Study

Published: July 12, 2017

CAMBRIDGE, Mass. (July 12, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Stanford Medicine in Stanford, CA has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Atman Desai, MD,  has been named Principal Investigator at the site. Dr. Desai is a Director of Neurosurgical Spinal Oncology and Clinical Assistant Professor of Neurosurgery at Stanford University Medical Center. Mark Perrin, InVivo’s CEO and Chairman, said, “We are pleased to welcome one of the most […]

View Article
InVivo Therapeutics Opens First Site in the United Kingdom for INSPIRE Study

Published: July 11, 2017

– Prominent Spinal Cord Researcher Manjunath Prasad and James Cook University Hospital Join INSPIRE – CAMBRIDGE, Mass. (July 11, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that James Cook University Hospital in Middlesbrough, United Kingdom has been added as the UK’s first clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The Golden Jubilee Regional Spinal Cord Injuries Centre located at the James Cook University Hospital, a major trauma center, focuses exclusively on patients with spinal cord injuries […]

View Article
InVivo Therapeutics Appoints Richard Toselli, M.D. as Chief Medical Officer

Published: July 10, 2017

CAMBRIDGE, Mass. (July 10, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Richard Toselli, M.D., as Chief Medical Officer, effective July 5, 2017. Dr. Toselli, a fellowship-trained spinal neurosurgeon, will assume all responsibilities related to the company’s clinical and regulatory strategy. Prior to joining InVivo, Dr. Toselli served as Chief Medical Officer for Cochlear Limited. In that role, he was responsible for global clinical, regulatory, and medical affairs teams reporting to the CEO. Prior to that, Dr. Toselli served five years at Sanofi in various levels of increasing responsibility, including Vice President of Global Medical Affairs – […]

View Article
InVivo Therapeutics Announces UCHealth Memorial Hospital as New Site for INSPIRE Study

Published: June 29, 2017

CAMBRIDGE, Mass. (June 29, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the UCHealth Memorial Hospital in Colorado Springs, CO has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.  Thomas Schroeppel, M.D., has been named Principal Investigator at the site. “I am thrilled to bring The INSPIRE Study and this innovative technology to the UCHealth Memorial Hospital, especially to help those who suffer from the devastating condition of spinal cord injury,” Dr. Schroeppel […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.